Search
Mira Pharmaceuticals Inc
MIRAAdd to Watchlist
0.780USD
+0.030+4.01%
Close 08-14 16:00（ET）Quotes delayed by 15 min
32.79MMarket Cap
LossP/E TTM
More Details of Mira Pharmaceuticals Inc Company
MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.
Mira Pharmaceuticals Inc Profile
Ticker SymbolMIRA
Company nameMIRA Pharmaceuticals Inc
IPO dateAug 03, 2023
CEOAminov (Erez)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endAug 03
Address1200 Brickell Avenue
CityMIAMI
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33131
Phone18133695150
Websitehttps://mirapharmaceuticals.com/
Ticker SymbolMIRA
IPO dateAug 03, 2023
CEOAminov (Erez)
Company Executives of Mira Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.20M
--
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.20M
--
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
150.00K
--
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
150.00K
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.20M
--
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
9.20M
--
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
150.00K
--
Dr. Denil Nanji Shekhat
Dr. Denil Nanji Shekhat
Director
Director
150.00K
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Mira Pharmaceuticals Inc?
The top five shareholders of Mira Pharmaceuticals Inc are: Mr. Erez Aminov
How many institutions hold shares of Mira Pharmaceuticals Inc (MIRA)?
As of 2026Q1, 52 institutions hold shares of Mira Pharmaceuticals Inc, with a combined market value of approximately 3.36M, accounting for 7.98% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 1195993.00.